Beijing Ji Quan Biotechnology

Beijing Jiquan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the research and development of innovative cell therapies. The company focuses on advancing CAR-T, TCR-T, and TIL (Tumor-Infiltrating Lymphocyte) technologies to address unmet medical needs in oncology. Its pipeline includes candidates targeting well-validated antigens such as CD19 and BCMA for hematological cancers, as well as GPC3 for solid tumors like hepatocellular carcinoma. Jiquan Biotechnology aims to enhance the efficacy of immunotherapies through proprietary genetic modifications designed to improve cell expansion and persistence. The firm operates modern R&D and manufacturing facilities to support its early-phase clinical trials.